Something's got to give: Psychiatric disease on the rise and novel drug development on the decline

Drug Discovery Today

Volumn 18, Issue 3-4, 2013, Pages 202-206

  Chandler, Daniel J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DRUG RESEARCH; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MENTAL DISEASE; PLACEBO EFFECT; PREVALENCE; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MENTAL DISORDERS; PLACEBO EFFECT; PSYCHOTROPIC DRUGS;

EID: 84873095820     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.08.003     Document Type: Review

References (53)

1. Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality The NSDUH Report: State Estimates of Adult Mental Illness 2012
2. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies and Inter-university Consortium for Political and Social Research National Survey on Drug Use and Health, 2008. In ICPSR 26701, Inter-university Consortium for Political and Social Research 2009 (distributor)
3. T.R. Insel Assessing the economic costs of serious mental illness Am. J. Psychiatry 165 2008 663 665
4. A. Soni Estimates for the U.S. Civilian Noninstitutionalized Population. Statistical Brief #248. July 2009 1996/2006 Agency for Healthcare Research and Quality Available at: http://www.meps.ahrq.gov/mepsweb/data-files/publications/ st248/stat248.pdf
5. J. Carroll AstraZeneca cutting 2,200 R&D jobs, slashing neuroscience in restructuring Fierce Biotech 2012 Available at: http://www.fiercebiotech.com/ story/astrazeneca-cutting-2200-rd-jobs-slashing-neuroscience-restructuring/ 2012-02-02
6. I. Cockburn Is the pharmaceutical industry in a productivity crisis? Innovation Policy and the Economy Vol. 7 2007 National Bureau of Economic Research, Inc. pp. 1-32
7. United States Congressional Budget Office Research and Development in the Pharmaceutical Industry 2006 The Office
8. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
9. D. Nutt, and G. Goodwin ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin Eur. Neuropsychopharmacol. 21 2011 495 499
10. M.N. Pangalos Drug development for CNS disorders: strategies for balancing risk and reducing attrition Nat. Rev. Drug Discov. 6 2007 521 532
11. R. Buller, and V. Legrand Novel treatments for anxiety and depression: hurdles in bringing them to the market Drug Discov. Today 6 2001 1220 1230
12. A.F. Jorm Mental health literacy. Public knowledge and beliefs about mental disorders Br. J. Psychiatry 177 2000 396 401
13. M.E. Coles, and S.L. Coleman Barriers to treatment seeking for anxiety disorders: initial data on the role of mental health literacy Depress. Anxiety 27 2010 63 71
14. D.P. Olsson, and M.G. Kennedy Mental health literacy among young people in a small US town: recognition of disorders and hypothetical helping responses Early Interv. Psychiatry 4 2010 291 298
15. T.W. Croghan American attitudes toward and willingness to use psychiatric medications J. Nerv. Ment. Dis. 191 2003 166 174
16. G. Miller Is Pharma running out of brainy ideas? Science 329 2010 502 504
17. M. Tartakovsky Depression: New Medications on the Horizon 2011 Psych Central Available at: http://psychcentral.com/lib/2011/depression-new- medications-on-the-horizon/all/1/
18. D.D. Schoepp Where will new neuroscience therapies come from? Nat. Rev. Drug Discov. 10 2011 715 716
19. S. Lee Depression research: where are we now? Mol. Brain 3 2010 8
20. P.M. Pitychoutis Pharmacogenetic insights into depression and antidepressant response: does sex matter? Curr. Pharm. Des. 16 2010 2214 2223
21. K. Chopra Pathobiological targets of depression Expert Opin. Ther. Targets 15 2011 379 400
22. M. Pytliak Serotonin receptors-from molecular biology to clinical applications Physiol. Res. 60 2011 15 25
23. D.F. Braus Neurobiology of depression Versicherungsmedizin 62 2010 3 8
24. F. Biedermann, and W.W. Fleischhacker Emerging drugs for schizophrenia Expert Opin. Emerg. Drugs 16 2011 271 282
25. H.H. Holcomb Cognitive dysfunction in schizophrenia: glutamatergic hypoactivity and dopaminergic failure Drug Discov. Today: Dis. Mech. 1 2004 435 439
26. J.K. Shin Schizophrenia: a systematic review of the disease state, current therapeutics and their molecular mechanisms of action Curr. Med. Chem. 18 2011 1380 1404
27. L. Citrome Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic Clin. Schizophr. Relat. Psychoses 4 2011 251 257
28. L.P. Sutton, and W.J. Rushlow The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling Neuroscience 199 2011 116 124
29. D.J. Lodge, and A.A. Grace Developmental pathology, dopamine, stress and schizophrenia Int. J. Dev. Neurosci. 29 2011 207 213
30. D.J. Lodge, and A.A. Grace Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia Trends Pharmacol. Sci. 32 2011 507 513
31. M.M. Nothen New findings in the genetics of major psychoses Dialogues Clin. Neurosci. 12 2010 85 93
32. V. Nieratschker New genetic findings in schizophrenia: is there still room for the dopamine hypothesis of schizophrenia? Front. Behav. Neurosci. 4 2010 23
33. K.S. Wang Genome-wide association analysis of age at onset in schizophrenia in a European-American sample Am. J. Med. Genet. B: Neuropsychiatr. Genet. 156B 2011 671 680
34. V. Moskvina Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk Mol. Psychiatry 14 2009 252 260
35. Y. Kitao A contribution to genome-wide association studies: search for susceptibility loci for schizophrenia using DNA microsatellite markers on chromosomes 19, 20, 21 and 22 Psychiatr. Genet. 10 2000 139 143
36. G. Kirov A genome-wide association study in 574 schizophrenia trios using DNA pooling Mol. Psychiatry 14 2009 796 803
37. D. Curtis Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes Psychiatr. Genet. 21 2011 1 4
38. A.L. Collins Hypothesis-driven candidate genes for schizophrenia compared to genome-wide association results Psychol. Med. 42 2011 607 616
39. C.S. Karam Signaling pathways in schizophrenia: emerging targets and therapeutic strategies Trends Pharmacol. Sci. 31 2010 381 390
40. S.C. Leiser Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research Biochem. Pharmacol. 81 2011 1408 1421
41. H. Hampel Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat. Rev. Drug Discov. 9 2010 560 574
42. I.A. Cook Early changes in prefrontal activity characterize clinical responders to antidepressants Neuropsychopharmacology 27 2002 120 131
43. M.J. Barbanoj Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario Methods Find. Exp. Clin. Pharmacol. 24 Suppl. D 2002 139 144
44. G.I. Papakostas Surrogate markers of treatment outcome in major depressive disorder Int. J. Neuropsychopharmacol. 15 2012 841 854
45. T. Sunderland Biomarkers in the diagnosis of Alzheimer's disease: are we ready? J. Geriatr. Psychiatry Neurol. 19 2006 172 179
46. A. Steiger, and M. Kimura Wake and sleep EEG provide biomarkers in depression J. Psych. Res. 44 2010 242 252
47. J. Deussing Animal models of depression Drug Discov. Today: Dis. Models 3 2006 375 383
48. L.C. Amann Mouse behavioral endophenotypes for schizophrenia Brain Res. Bull. 83 2010 147 161
49. J.D. Mikkelsen Use of biomarkers in the discovery of novel anti-schizophrenia drugs Drug Discov. Today 15 2010 137 141
50. R. McArthur Many are called, yet few are chosen. Are neuropsychiatric clinical trials letting us down? Drug Discov. Today 16 2011 173 175
51. J. Moncrieff Active placebos versus antidepressants for depression Cochrane Database Syst. Rev. 1 2004 CD003012
52. M.A. Posternak, and I. Miller Untreated short-term course of major depression: a meta-analysis of outcomes from studies using wait-list control groups J. Affect. Disord. 66 2001 139 146
53. M. Samwald Linked open drug data for pharmaceutical research and development J. Cheminform. 3 2011 19